{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:49:51Z","timestamp":1790668191067,"version":"4.1.0"},"reference-count":76,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T00:00:00Z","timestamp":1648080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Surg."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Euglycemic diabetic ketoacidosis (EDKA) is a potentially life-threatening condition and a reported side effect of antidiabetic sodium-glucose-cotransporter-2-inhibitors (SGLT2-I). The analysis of the herein presented case and its management formed the incentive to prepare this multidisciplinary work and includes an overview about perioperative SGLT2-I-induced ketoacidosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>A PubMed search on relevant entries was conducted combining the terms \u201ceuglycemic diabetic ketoacidosis\u201d AND \u201csurgery.\u201d<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 33 articles on SGLT2-I-induced ketoacidosis in the context of surgical treatment were identified. According to this literature research risk factors for the development are infection, perioperative fasting, surgical stress, and insulin dose reduction.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Unspecific symptoms mimicking acute abdomen and normoglycemia can lead to delayed diagnosis of EDKA and might harm patients under SGLT2-I therapy in the perioperative setting. SGLT2-I medication should be withheld for at least 24\u201348 h prior to surgery according to this review of literature and restarted only in stable clinical conditions to avoid the severe complication of EDKA.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fsurg.2022.828649","type":"journal-article","created":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T05:26:35Z","timestamp":1648531595000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["New Diabetic Medication Sodium-Glucose Cotransporter-2 Inhibitors Can Induce Euglycemic Ketoacidosis and Mimic Surgical Diseases: A Case Report and Review of Literature"],"prefix":"10.3389","volume":"9","author":[{"given":"Antonia-Therese","family":"Kietaibl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Fasching","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Glaser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander H.","family":"Petter-Puchner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jemermed.2017.10.001","article-title":"Euglycemic diabetic ketoacidosis secondary to dapagliflozin use: a case report","volume":"54","author":"Brown","year":"2018","journal-title":"J Emerg Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e929773","DOI":"10.12659\/AJCR.929773","article-title":"Life-Threatening complications related to delayed diagnosis of euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitors: a report of 2 cases","volume":"22","author":"Goto","year":"2021","journal-title":"Am J Case Rep."},{"key":"B3","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s11604-015-0489-z","article-title":"The practice guidelines for primary care of acute abdomen 2015","volume":"34","author":"Mayumi","year":"2016","journal-title":"Jpn J Radiol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"509","DOI":"10.4183\/aeb.2017.509","article-title":"Diabetic ketoacidosis with an acute abdomen as a first manifestation of type 1 diabetes mellitus","volume":"13","author":"Csomor","year":"2017","journal-title":"Acta Endocrinol Buchar Rom."},{"key":"B5","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1001\/jama.233.2.166","article-title":"Abdominal pain in diabetic metabolic decompensation: clinical significance","volume":"233","author":"Campbell","year":"1975","journal-title":"JAMA."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.3748\/wjg.v27.i14.1362","article-title":"How far along are we in revealing the connection between metformin and colorectal cancer?","volume":"27","author":"Berkovic","year":"2021","journal-title":"World J Gastroenterol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/j.jvs.2021.03.033","article-title":"Geographical socioeconomic disadvantage is associated with adverse outcomes following major amputation in diabetic patients","volume":"74","author":"Zhang","year":"2021","journal-title":"J Vasc Surg."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1001\/jama.2021.7912","article-title":"The Push for Earlier Bariatric Surgery for Adolescents With Severe Obesity","volume":"325","author":"Jaklevic","year":"2021","journal-title":"JAMA."},{"key":"B9","unstructured":"European Medicines Agency2018"},{"key":"B10","unstructured":"FDA Approval History. Drugs.com"},{"key":"B11","unstructured":"FDA Approval History. Drugs.com"},{"key":"B12","unstructured":"European Medicines Agency2018"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1007\/s00125-018-4669-0","article-title":"The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure","volume":"61","author":"Thomas","year":"2018","journal-title":"Diabetologia."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med."},{"key":"B19","unstructured":"\u00d6DG Leitlinien"},{"key":"B20","doi-asserted-by":"publisher","first-page":"S111","DOI":"10.2337\/dc21-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-\u22122021","volume":"44","year":"2021","journal-title":"Diabetes Care."},{"key":"B21","unstructured":"IDF Atlas 9th Edition and Other Resources"},{"key":"B22","doi-asserted-by":"publisher","first-page":"248","DOI":"10.7326\/M18-3136","article-title":"Sodium\u2013Glucose cotransporter-2 inhibitors and the risk for severe urinary tract infections","volume":"171","author":"Dave","year":"2019","journal-title":"Ann Intern Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e000725","DOI":"10.1136\/bmjdrc-2019-000725","article-title":"Pharmacovigilance assessment of the association between fournier's gangrene and other severe genital adverse events with SGLT-2 inhibitors","volume":"7","author":"Fadini","year":"2019","journal-title":"BMJ Open Diabetes Res Care."},{"key":"B24","doi-asserted-by":"publisher","first-page":"417","DOI":"10.7326\/M20-0289","article-title":"Sodium\u2013Glucose cotransporter-2 inhibitors and the risk for diabetic ketoacidosis","volume":"173","author":"Douros","year":"2020","journal-title":"Ann Intern Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e13665","DOI":"10.7759\/cureus.13665","article-title":"Euglycemic diabetic ketoacidosis and sodium-glucose cotransporter-2 inhibitors: a focused review of pathophysiology, risk factors, and triggers","volume":"13","author":"Somagutta","year":"2021","journal-title":"Cureus."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e2886","DOI":"10.1002\/dmrr.2886","article-title":"Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: basic mechanisms and therapeutic perspectives","volume":"33","author":"Qiu","year":"2017","journal-title":"Diabetes Metab Res Rev."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1002\/ccr3.2147","article-title":"Euglycemic diabetic ketoacidosis in association with dapagliflozin use after gastric sleeve surgery in a patient with type II diabetes mellitus","volume":"7","author":"Banakh","year":"2019","journal-title":"Clin Case Rep."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1210\/js.2019-SUN-177","article-title":"SUN-177 house of carbs: the path to euglycemic Dka in patients with diabetes on Sglt2 inhibitors","author":"Islam","year":"2019","journal-title":"J Endocr Soc."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e1747850","DOI":"10.1155\/2018\/1747850","article-title":"Euglycemic diabetic ketoacidosis in the ICU: 3 case reports and review of literature","volume":"2018","author":"Lucero","year":"2018","journal-title":"Case Rep Crit Care."},{"key":"B30","doi-asserted-by":"publisher","first-page":"NC01","DOI":"10.7860\/JCDR\/2014\/8609.5229","article-title":"Efficacy of mannheim peritonitis index (MPI) score in patients with secondary peritonitis","volume":"8","author":"Muralidhar","year":"2014","journal-title":"J Clin Diagn Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1213\/XAA.0000000000000734","article-title":"When guidelines fail: euglycemic diabetic ketoacidosis after bariatric surgery in a patient taking a sodium\u2013glucose cotransporter-2 inhibitor: a case report","volume":"11","author":"Lane","year":"2018","journal-title":"A A Pract."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e14297","DOI":"10.7759\/cureus.14297","article-title":"Post-Operative euglycemic diabetic ketoacidosis in a patient with SGLT-2 inhibitor use and recent sleeve gastrectomy","volume":"13","author":"Smith","year":"2021","journal-title":"Cureus."},{"key":"B33","doi-asserted-by":"publisher","first-page":"3848","DOI":"10.1007\/s11695-021-05391-0","article-title":"Two cases of euglycemic diabetic ketoacidosis after bariatric surgery associated with sodium-glucose cotransporter-2 inhibitor use","volume":"31","author":"Amianda","year":"2021","journal-title":"Obes Surg."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e10878","DOI":"10.7759\/cureus.10878","article-title":"Euglycemic diabetic ketoacidosis with sodium-glucose cotransporter-2 inhibitor use post-bariatric surgery: a brief review of the literature","volume":"12","author":"Iqbal","year":"2020","journal-title":"Cureus."},{"key":"B35","doi-asserted-by":"publisher","first-page":"8817829","DOI":"10.1155\/2020\/8817829","article-title":"SGLT-2 inhibitors\u2014a culprit of diabetic ketoacidosis postbariatric surgery","volume":"2020","author":"Iqbal","year":"2020","journal-title":"Case Rep Crit Care."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e17093","DOI":"10.7759\/cureus.17093","article-title":"Sodium-Glucose co-transporter 2 inhibitor-associated euglycemic diabetic ketoacidosis after bariatric surgery: a case and literature review","volume":"13","author":"Kapila","year":"2021","journal-title":"Cureus."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1177\/0003134820940286","article-title":"Euglycemic diabetic ketoacidosis associated with use of SGLT2 inhibitor after laparoscopic roux-en-Y gastric bypass","volume":"87","author":"Yared","year":"2020","journal-title":"Am Surg."},{"key":"B38","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/jdi.13365","article-title":"Early detection of euglycemic ketoacidosis during thoracic surgery associated with empagliflozin in a patient with type 2 diabetes: a case report","volume":"12","author":"Kitahara","year":"2021","journal-title":"J Diabetes Investig."},{"key":"B39","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.dsx.2021.04.016","article-title":"Empagliflozin induced euglycemic diabetic ketoacidosis in a patient undergoing coronary artery bypass graft despite discontinuation of the drug 48 hours prior to the surgery","volume":"15","author":"Kuchay","year":"2021","journal-title":"Diabetes Metab Syndr Clin Res Rev."},{"key":"B40","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.aace.2020.11.014","article-title":"A case of SGLT2 inhibitor-associated euglycemic diabetic ketoacidosis following coronary artery bypass surgery","volume":"7","author":"Osafehinti","year":"2020","journal-title":"AACE Clin Case Rep."},{"key":"B41","doi-asserted-by":"publisher","first-page":"110201","DOI":"10.1016\/j.jclinane.2021.110201","article-title":"Perioperative euglycemic diabetic ketoacidosis following use of SGLT-2 inhibitors after cardiac surgery","volume":"71","author":"Pontes","year":"2021","journal-title":"J Clin Anesth."},{"key":"B42","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s12055-021-01227-9","article-title":"Insulin and glucose infusion could prevent euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter 2 inhibitors","volume":"38","author":"Ito","year":"2022","journal-title":"Indian J Thorac Cardiovasc Surg."},{"key":"B43","doi-asserted-by":"publisher","first-page":"2086520","DOI":"10.1155\/2021\/2086520","article-title":"Euglycemic diabetic ketoacidosis in a sedated patient after coronary artery bypass grafting: a case report and literature review","volume":"2021","author":"Alabdaljabar","year":"2021","journal-title":"Case Rep Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1007\/s12630-017-1018-6","article-title":"Perioperative implications of sodium-glucose cotransporter-2 inhibitors: a case series of euglycemic diabetic ketoacidosis in three patients after cardiac surgery","volume":"65","author":"Lau","year":"2018","journal-title":"Can J Anesth Can Anesth."},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1053\/j.jvca.2021.07.048","article-title":"Euglycemic diabetic ketoacidosis after cardiac surgery in a patient treated with empagliflozin for type 2 diabetes mellitus: a case report","author":"Wohlrab","year":"2021","journal-title":"J Cardiothorac Vasc Anesth."},{"key":"B46","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1016\/j.transproceed.2021.08.017","article-title":"Sodium-Glucose cotransporter-2 inhibitor\u2013associated euglycemic diabetic ketoacidosis after orthotopic heart transplant in a prediabetic patient: a case report","volume":"53","author":"Cha","year":"2021","journal-title":"Transplant Proc."},{"key":"B47","doi-asserted-by":"publisher","first-page":"e4496","DOI":"10.7759\/cureus.4496","article-title":"Post-surgical euglycemic diabetic ketoacidosis in a patient on empagliflozin in the intensive care unit","volume":"11","author":"Bteich","year":"2019","journal-title":"Cureus."},{"key":"B48","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1177\/1941874419835035","article-title":"Postoperative euglycemic diabetic ketoacidosis and encephalopathy related to SGLT-2 inhibitors: a case report and discussion of diabetes treatment and \u201csweet pee encephalopathy\u201d in perioperative hospital management","volume":"10","author":"Mackintosh","year":"2020","journal-title":"Neurohospitalist."},{"key":"B49","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1530\/EDM-19-0087","article-title":"Prolonged acidosis is a feature of SGLT2i-induced euglycaemic diabetic ketoacidosis","volume":"2019","author":"Rafey","year":"2019","journal-title":"Endocrinol Diabetes Metab Case Rep."},{"key":"B50","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.jvscit.2021.10.006","article-title":"Euglycemic diabetic ketoacidosis following major vascular surgery is a new item on the differential for postoperative acidosis","volume":"7","author":"Gomez-Sanchez","year":"2021","journal-title":"J Vasc Surg Cases Innov Tech."},{"key":"B51","doi-asserted-by":"publisher","first-page":"e25590","DOI":"10.1097\/MD.0000000000025590","article-title":"Postoperative extremity gangrene in a patient with type 2 diabetes taking SGLT2 inhibitors","volume":"100","author":"Wong","year":"2021","journal-title":"Medicine."},{"key":"B52","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1111\/iju.14624","article-title":"Sodium glucose-linked transport protein 2 inhibitors: an overview of genitourinary and perioperative implications","volume":"28","author":"Chandrashekar","year":"2021","journal-title":"Int J Urol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"e15533","DOI":"10.7759\/cureus.15533","article-title":"Postoperative euglycemic ketoacidosis in type 2 diabetes associated with sodium-glucose cotransporter 2 inhibitor: insights into pathogenesis and management strategy","volume":"13","author":"Chandrakumar","year":"2021","journal-title":"Cureus"},{"key":"B54","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1089\/pancan.2018.0016","article-title":"Euglycemic diabetic ketoacidosis due to sodium\u2013glucose cotransporter 2 inhibitor use in two patients undergoing pancreatectomy","volume":"4","author":"Pace","year":"2018","journal-title":"J Pancreat Cancer."},{"key":"B55","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s12882-020-01930-6","article-title":"Severe euglycemic diabetic ketoacidosis of multifactorial etiology in a type 2 diabetic patient treated with empagliflozin: case report and literature review","volume":"21","author":"Sampani","year":"2020","journal-title":"BMC Nephrol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s00228-020-03051-3","article-title":"Predisposing factors for the development of diabetic ketoacidosis with lower than anticipated glucose levels in type 2 diabetes patients on SGLT2-inhibitors: a review","volume":"77","author":"Bamgboye","year":"2021","journal-title":"Eur J Clin Pharmacol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"102275","DOI":"10.1016\/j.dsx.2021.102275","article-title":"Clinical and biochemical characteristics and analysis of risk factors for euglycaemic diabetic ketoacidosis in type 2 diabetic individuals treated with SGLT2 inhibitors: a review of 72 cases over a 4.5-year period","volume":"15","author":"Menghoum","year":"2021","journal-title":"Diabetes Metab Syndr Clin Res Rev."},{"key":"B58","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1016\/j.clinthera.2016.11.002","article-title":"SGLT2 inhibitor\u2013associated diabetic ketoacidosis: clinical review and recommendations for prevention and diagnosis","volume":"38","author":"Goldenberg","year":"2016","journal-title":"Clin Ther."},{"key":"B59","doi-asserted-by":"publisher","first-page":"514","DOI":"10.4239\/wjd.v12.i5.514","article-title":"Euglycemic diabetic ketoacidosis: a missed diagnosis","volume":"12","author":"Nasa","year":"2021","journal-title":"World J Diabetes."},{"key":"B60","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1210\/clinem\/dgaa200","article-title":"Evolving evidence of diabetic ketoacidosis in patients taking sodium-glucose cotransporter 2 inhibitors","volume":"105","author":"Fleming","year":"2020","journal-title":"J Clin Endocrinol Metab."},{"key":"B61","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ajem.2021.02.015","article-title":"Euglycemic diabetic ketoacidosis: etiologies, evaluation, and management","volume":"44","author":"Long","year":"2021","journal-title":"Am J Emerg Med."},{"key":"B62","unstructured":"FDAFDA Revises Labels of SGLT2 Inhibitors for Diabetes to Include Warnings About Too Much Acid in the Blood and Serious Urinary Tract Infections2021"},{"key":"B63","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1136\/bmj.2.5866.578","article-title":"Euglycaemic diabetic ketoacidosis","volume":"2","author":"Munro","year":"1973","journal-title":"BMJ."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1111\/dom.13224","article-title":"Intra- and inter-subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co-transporter 2 inhibitor canagliflozin","volume":"20","author":"Polidori","year":"2018","journal-title":"Diabetes Obes Metab."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1007\/s13300-020-00889-9","article-title":"Are SGLT-2 inhibitors the future of heart failure treatment? The EMPEROR-preserved and EMPEROR-reduced trials","volume":"11","author":"Williams","year":"2020","journal-title":"Diabetes Ther."},{"key":"B66","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.cmet.2020.06.020","article-title":"SGLT2 inhibition mediates protection from diabetic kidney disease by promoting ketone body-induced mTORC1 inhibition","volume":"32","author":"Tomita","year":"2020","journal-title":"Cell Metab."},{"key":"B67","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"m4573","DOI":"10.1136\/bmj.m4573","article-title":"Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials","volume":"372","author":"Palmer","year":"2021","journal-title":"BMJ."},{"key":"B69","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1016\/j.bja.2021.03.023","article-title":"Metabolic outcomes in patients with diabetes mellitus administered SGLT2 inhibitors immediately before emergency or elective surgery: single centre experience and recommendations","volume":"127","author":"Wang","year":"2021","journal-title":"Br J Anaesth."},{"key":"B70","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1007\/s00508-019-1459-8","article-title":"Positionspapier: operation und diabetes mellitus (update 2019)","volume":"131","author":"Fasching","year":"2019","journal-title":"Wien Klin Wochenschr."},{"key":"B71","unstructured":"Diabetes CareDiabetes Care in the Hospital: Standards of Medical Care in Diabetes\u22122021"},{"key":"B72","doi-asserted-by":"publisher","first-page":"753","DOI":"10.4158\/EP161292.PS","article-title":"American association of clinical endocrinologists and American college of endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis","volume":"22","author":"Handelsman","year":"2016","journal-title":"Endocr Pract."},{"key":"B73","unstructured":"Australian Diabetes SocietySevere Euglycaemic Ketoacidosis With SGLT2 Inhibitor Use in the Perioperative Period2018"},{"key":"B74","unstructured":"TraillDR\n          Severe Euglycaemic Ketoacidosis With SGLT2 Inhibitor Use in the Perioperative Period2022"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1111\/anae.14251","article-title":"Sodium-glucose co-transporter type-2 inhibitors: pharmacology and peri-operative considerations","volume":"73","author":"Milder","year":"2018","journal-title":"Anaesthesia."},{"key":"B76","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/phar.1881","article-title":"SGLT2 inhibitors: a systematic review of diabetic ketoacidosis and related risk factors in the primary literature","volume":"37","author":"Burke","year":"2017","journal-title":"Pharmacother J Hum Pharmacol Drug Ther."}],"container-title":["Frontiers in Surgery"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fsurg.2022.828649\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T05:26:45Z","timestamp":1648531605000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fsurg.2022.828649\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,24]]},"references-count":76,"alternative-id":["10.3389\/fsurg.2022.828649"],"URL":"https:\/\/doi.org\/10.3389\/fsurg.2022.828649","relation":{},"ISSN":["2296-875X"],"issn-type":[{"value":"2296-875X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,24]]},"article-number":"828649"}}